| Literature DB >> 28255550 |
Jad A Degheili1, Nadim A Kanj1, Salwa A Koubaissi1, Mouhamad J Nasser1.
Abstract
Inflammatory pseudotumor (IPT) has always been considered a diagnostic challenge. Its rarity and resemblance to other more common pathological entities imposes that neither clinical nor radiological characteristics can lead to a definitive diagnosis. The surgical excision of the lesion is the ultimate approach for accurate diagnosis and cure. Moreover the true nature of IPT, its origin as a neoplastic entity or an over-reactive inflammatory reaction to an unknown trigger, has been a long debated matter. Surgery remains the treatment of choice. IPT is mostly an indolent disease with minimal morbidity and mortality. Local invasion and metastasis predict a poor prognosis. We hereby present a unique case of pulmonary IPT that was surgically excised, but recurred contralaterally, shortly thereafter. Despite no medical or surgical treatment for ten years, the lesion has remained stable in size, with neither symptoms nor extra-pulmonary manifestations.Entities:
Keywords: Anaplastic lymphoma kinase; IgG4-related sclerosing disease; Inflammatory myofibroblastic tumor; Inflammatory pseudotumor; Plasma cells granuloma
Year: 2017 PMID: 28255550 PMCID: PMC5314263 DOI: 10.12998/wjcc.v5.i2.61
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Figure 1Initial lung resection revealing diffuse infiltration of inflammatory cells and undifferentiated fibroblasts, representing acute and chronic non-specific inflammation, along with fibrosis (A: 10 ×; B: 40 × magnification).
Figure 2Computed tomography of the chest revealing a right middle lobe mass (arrow), with multiple calcified hilar and mediastinal lymph nodes (arrow heads).
Figure 3(A) Heavy infiltration of lymphocytes, plasma cells, and histiocytes, within a background of spindle-shaped fibroblasts and myofibroblasts, arrayed in fascicles (B). Immunostaining of tissues showing positivity for CD3 (B1), negativity for CD20 (B2), and positivity for CD138 (B3), respectively.